报价延迟最少15分钟:2026/04/26 07:00 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.68 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.59/-0.26
|
|
企业价值
202.33M
|
| 资产负债 |
|
每股账面净值
0.32
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
149.16M
|
|
每股收益
1.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services. |
